Imago BioSciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Imago BioSciences, a clinical-stage biopharmaceutical company focused on myeloproliferative neoplasms, announced CEO Hugh Young Rienhoff, Jr. will present at two upcoming investor conferences:

• H.C. Wainwright 3rd Annual Precision Oncology Conference: November 14 at 12:30 pm ET
• Stifel Healthcare Conference: November 16 at 8:00 am ET

Live webcasts will be accessible on the company's website, with replays available for 90 days. Imago is developing Bomedemstat, a drug for treating blood cancers, currently in Phase 2 trials.

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in two upcoming investor conferences.

Details of the events are as follows:

H.C. Wainwright 3^rd Annual Precision Oncology Conference. Dr. Rienhoff will present on Monday, November 14 at 12:30 pm ET.

Stifel Healthcare Conference. Dr. Rienhoff will present on Wednesday, November 16^th at 8:00 am ET.

Interested parties can access the live webcasts for these conferences from the Investor Relations section of the company's website at www.imagobio.com. The webcast replays will be available after the conclusion of each conference for approximately 90 days.

About Imago BioSciences
Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in Redwood City, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.

Contacts:
Media Contact:
Will Zasadny
Evoke Canale
Will.zasadny@evokegroup.com

Investor Contact:
Laurence Watts
Gilmartin Group, LLC.
Laurence@gilmartinir.com 

FAQ

What is Imago BioSciences presenting at the H.C. Wainwright Conference?

Imago BioSciences will have CEO Hugh Young Rienhoff, Jr. presenting on November 14 at 12:30 pm ET.

When will Imago BioSciences present at the Stifel Healthcare Conference?

Imago BioSciences will present on November 16 at 8:00 am ET.

How can I access the webcasts of Imago BioSciences' presentations?

The live webcasts can be accessed in the Investor Relations section of Imago BioSciences' website.

What is the focus of Imago BioSciences?

Imago BioSciences focuses on discovering and developing treatments for myeloproliferative neoplasms and other bone marrow diseases.

What is Bomedemstat and its significance for Imago BioSciences?

Bomedemstat is a lead drug candidate aimed at treating myeloproliferative neoplasms, currently undergoing Phase 2 trials.